Published in Oncogene on May 13, 2002
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood (2008) 2.00
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal (2016) 1.30
The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood (2007) 1.22
HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics (2011) 1.19
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood (2012) 1.16
The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle (2009) 1.13
Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol (2010) 1.09
The role of the RB tumour suppressor pathway in oxidative stress responses in the haematopoietic system. Nat Rev Cancer (2008) 1.08
TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood (2010) 1.01
Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. Curr Genomics (2009) 1.01
TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J Haematol (2006) 0.96
Homozygous and heterozygous p53 knockout rats develop metastasizing sarcomas with high frequency. Am J Pathol (2011) 0.93
DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome. J Korean Med Sci (2011) 0.90
Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nat Commun (2015) 0.89
Effect of p27(KIP1) on cell cycle and apoptosis in gastric cancer cells. World J Gastroenterol (2005) 0.88
A cascade of modules of a network defines cancer progression. Cancer Res (2006) 0.85
In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML. PLoS One (2010) 0.85
Rats deficient for p53 are susceptible to spontaneous and carcinogen-induced tumorigenesis. Carcinogenesis (2012) 0.83
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Cell Stem Cell (2015) 0.82
Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A. J Korean Med Sci (2013) 0.81
Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp Hematol (2016) 0.79
RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines. J Cancer Res Clin Oncol (2011) 0.77
Down-regulation of GPX3 is associated with favorable/intermediate karyotypes in de novo acute myeloid leukemia. Int J Clin Exp Pathol (2015) 0.77
The DAC system and associations with acute leukemias and myelodysplastic syndromes. Invest New Drugs (2010) 0.77
Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia. Int J Clin Exp Pathol (2015) 0.77
Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study. Medicine (Baltimore) (2015) 0.76
Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization. PLoS One (2011) 0.76
Identification of novel genomic aberrations in AML-M5 in a level of array CGH. PLoS One (2014) 0.76
Hemizygosity for Atm and Brca1 influence the balance between cell transformation and apoptosis. Radiat Oncol (2010) 0.76
Direct regulation of p53 by miR-142a-3p mediates the survival of hematopoietic stem and progenitor cells in zebrafish. Cell Discov (2015) 0.76
Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype. Am J Hematol (2011) 0.75
The DN2 Myeloid-T (DN2mt) Progenitor is a Target Cell for Leukemic Transformation by the TLX1 Oncogene. J Bone Marrow Res (2013) 0.75
PIN3 duplication may be partially responsible for TP53 haploinsufficiency. BMC Cancer (2014) 0.75
Intronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response. J Nat Sci Biol Med (2012) 0.75
Studies of Tumor Suppressor Genes via Chromosome Engineering. Cancers (Basel) (2015) 0.75
Tumor immunology viewed from alternative animal models-the Xenopus story. Curr Pathobiol Rep (2017) 0.75
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 13.02
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet (2004) 9.35
Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation (2006) 5.99
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet (2006) 4.43
Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J (2005) 4.36
Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation (2005) 4.20
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood (2011) 3.32
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol (2011) 3.17
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.97
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood (2006) 2.87
The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell (2006) 2.71
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood (2012) 2.69
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood (2007) 2.46
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol (2010) 2.38
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis (2009) 2.34
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol (2011) 2.26
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol (2009) 2.23
Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res (2007) 2.21
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood (2006) 2.15
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet (2013) 2.14
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood (2013) 2.12
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol (2011) 2.11
Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol (2009) 2.07
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene (2005) 2.06
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood (2002) 2.03
Differentiation therapy of leukemia: 3 decades of development. Blood (2009) 2.02
Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood (2004) 1.99
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood (2010) 1.96
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. Disaster Med Public Health Prep (2011) 1.93
Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci U S A (2002) 1.92
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res (2004) 1.85
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood (2012) 1.85
Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis (2005) 1.83
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res (2006) 1.82
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol (2011) 1.79
Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One (2007) 1.79
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med (2013) 1.79
Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J (2009) 1.78
Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res (2006) 1.74
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood (2013) 1.74
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer (2007) 1.72
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood (2009) 1.70
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood (2010) 1.70
Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res (2004) 1.68
Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol (2004) 1.68
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A (2008) 1.65
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol (2010) 1.64
In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. Int J Cancer (2007) 1.64
C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res (2002) 1.64
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica (2011) 1.63
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood (2013) 1.62
Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood (2002) 1.60
Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leuk Res (2005) 1.56
BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med (2010) 1.56
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood (2010) 1.56
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol (2008) 1.55
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood (2005) 1.53
Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem (2007) 1.53
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res (2007) 1.53
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res (2004) 1.50
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood (2003) 1.50
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res (2006) 1.45
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol (2005) 1.45
Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur Heart J (2008) 1.45
Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood (2011) 1.44
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood (2007) 1.44
The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol (2004) 1.43
Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res (2009) 1.43
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica (2008) 1.41
Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood (2003) 1.40
Evaluation of tissue factor bearing microparticles as biomarkers in allogeneic stem-cell transplantation. Transplantation (2011) 1.39
G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood (2003) 1.38
MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood (2007) 1.37
Myelodysplastic syndrome. Annu Rev Med (2005) 1.37
A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther (2007) 1.36
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood (2007) 1.36
How I treat the acquired von Willebrand syndrome. Blood (2011) 1.36
A role for the clock gene per1 in prostate cancer. Cancer Res (2009) 1.35
Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood (2005) 1.35
Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci U S A (2008) 1.34
Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood (2004) 1.33